1. Home
  2. REF vs ANL Comparison

REF vs ANL Comparison

Compare REF & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reformation Inc. Common Stock

REF

Reformation Inc. Common Stock

N/A

Current Price

$13.60

Market Cap

904.5M

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$10.83

Market Cap

998.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
REF
ANL
Founded
2009
2004
Country
United States
Singapore
Employees
N/A
N/A
Industry
Apparel
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
904.5M
998.8M
IPO Year
2026
2022

Fundamental Metrics

Financial Performance
Metric
REF
ANL
Price
$13.60
$10.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
7
Target Price
$19.25
★ $29.50
AVG Volume (30 Days)
★ 555.6K
225.3K
Earning Date
11-03-2026
08-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$19.39
$243.83
Revenue Next Year
$16.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.85
$0.88
52 Week High
$17.26
$17.25

Technical Indicators

Market Signals
Indicator
REF
ANL
Relative Strength Index (RSI) 50.77 30.35
Support Level $12.90 $8.96
Resistance Level $16.24 $12.49
Average True Range (ATR) 0.61 1.37
MACD 0.18 -0.51
Stochastic Oscillator 73.54 1.73

Price Performance

Historical Comparison
REF
ANL

About REF Reformation Inc. Common Stock

Reformation Inc sells apparel and accessories through its website, company-owned retail stores, wholesale channels, and other distribution channels in the United States and internationally. Its product portfolio includes dresses, bottoms, tops, sweaters, and accessories. The company focuses on womenswear and sources materials and products through its supply chain operations. The majority of the company's revenue was derived from the sale of its apparel and accessories, including clothing, shoes, and bags, through e-commerce and retail. Geographically, the maximum revenue is generated from the United States.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: